Mdxhealth Sa (MXDHF) 3.6900 $MXDHF
MDxHealth (R): Grants QIAGEN Rights to MSP Technology for QIAsure Methylation Test for Cervical Cancer Risk
GlobeNewswire - Wed Jun 15, 12:07AM CDT
MDxHealth SA (Euronext: MDXH.BR), announced today that it has granted a non-exclusive worldwide license for its patented methylation-specific PCR (MSP) technology to QIAGEN for use in its new CE-marked QIAsure assay to determine cervical cancer risk.
MDxHealth Secures First Reimbursement Coverage for SelectMDx
GlobeNewswire - Tue Jun 14, 12:13AM CDT
MDxHealth SA (Euronext: MDXH.BR), announced today that it has secured the first U.S. reimbursement coverage agreement for its SelectMDx(TM) for Prostate Cancer test with America's Choice Provider Network, Inc. (ACPN). ACPN is a national provider network with over 1,700 payers, including insurance carriers, third party administrators, health and welfare funds, employer groups and self-insured health plans, providing coverage to 24 million American lives and 750,000 international lives.
MDxHealth (R): Disclosure of the Number of Outstanding Voting Securities
GlobeNewswire - Fri May 20, 12:05AM CDT
MDxHealth SA (NYSE Euronext: MDXH) ("MDxHealth"
announced today, pursuant to Article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated market, that on May 19, 2016, 116,000 new ordinary shares were issued by MDxHealth further to the exercise of 116,000 warrants by employees and consultants of MDxHealth, for an aggregate exercise price of EUR 196,920.00 for all warrants. The exercised warrants were initially issued in April 2011 and May 2012.
Taglich Brothers Initiates Coverage on MDxHealth SA
Marketwire Canada - Mon May 09, 8:30AM CDT
NEW YORK, NY--(Marketwired - May 09, 2016) - Taglich Brothers, Inc. announces it initiated coverage of MDxHealth SA (EURONEXT BRUSSELS: MDXH)(OTC: MDXHF).
MDxHealth's ConfirmMDx Stratifies Risk for Aggressive Prostate Cancer
GlobeNewswire - Mon May 09, 12:07AM CDT
MDxHealth SA (Euronext: MDXH.BR) announced today the publication of multicenter validation data demonstrating that ConfirmMDx(R) for Prostate Cancer can aid in the identification of men with clinically significant prostate cancer (PCa) in the journal The Prostate.
MDxHealth Announces Positive Data Supporting Prognostic Value of ConfirmMDx and SelectMDx for Prostate Cancer
GlobeNewswire - Fri May 06, 12:09AM CDT
MDxHealth SA (Euronext: MDXH.BR) is presenting positive data demonstrating the prognostic value of its SelectMDx and ConfirmMDx tests for Prostate Cancer test at the 2016 American Urological Association Annual Meeting hold between 6-10 May 2016 in San Diego, California, USA. These data, which are presented in two separate poster presentations, demonstrate that:
MDxHealth Provides First Quarter 2016 Business Update
GlobeNewswire - Tue May 03, 12:11AM CDT
MDxHealth SA (Euronext: MDXH.BR) today issued its business update for the quarter ended March 31, 2016.
MDxHealth's SelectMDx Study Published in European Urology
GlobeNewswire - Mon Apr 25, 12:08AM CDT
MDxHealth SA (Euronext: MDXH.BR), today announced that data validating the clinical performance of the SelectMDx(TM) for Prostate Cancer test have been published in European Urology.
MDxHealth Partners with Andros Men's Clinic to Offer SelectMDx for Prostate Cancer
GlobeNewswire - Tue Mar 29, 12:08AM CDT
MDxHealth SA (Euronext: MDXH.BR), announced today that it has partnered with Andros Men's Health Clinic (Andros Mannenkliniek) in The Netherlands to offer the SelectMDx for Prostate Cancer test to their patients.
MDxHealth Launches SelectMDx "Liquid Biopsy" Test in the United States
GlobeNewswire - Thu Mar 17, 1:05AM CDT
MDxHealth SA (Euronext: MDXH.BR), today announced the commercial launch of its SelectMDx(TM) for Prostate Cancer test in the United States as a laboratory developed test (LDT). Testing will be conducted at MDxHealth's state-of-the-art CAP and CLIA accredited laboratory facilities in Irvine, California.
MDxHealth Presents SelectMDx(TM) Results from Multicenter Validation Study at the 2016 Annual EAU Congress
GlobeNewswire - Mon Mar 14, 1:11AM CDT
MDxHealth SA (Euronext: MDXH.BR), announced today that positive results of a prospective, multicenter validation study of SelectMDx(TM) for Prostate Cancer were presented at the 2016 Annual European Association of Urology (EAU) Congress, March 11-15 in Munich, Germany.
MDxHealth Appoints Global Commercial Team for SelectMDx
GlobeNewswire - Wed Mar 09, 12:04AM CST
MDxHealth SA (Euronext: MDXH.BR) announced today that it has appointed a global commercial team to drive the launch of the Company's new non-invasive, urine-based test, SelectMDx(TM) for Prostate Cancer.
MDxHealth Announces Conference Participation for First Half 2016
GlobeNewswire - Thu Jan 28, 2:06AM CST
MDxHealth SA (Euronext: MDXH.BR), announced today that it will be participating at the following key conferences during the first half of 2016:
Frost & Sullivan Applauds MDxHealth's Commitment to Improving Prostrate Cancer Detection through its ConfirmMDx and SelectMDx Tests
PR Newswire Europe - Thu Jan 21, 8:01AM CST
A positive ConfirmMDx or SelectMDx test can indicate whether the patient is at risk of harboring an aggressive or non-aggressive cancer
MDxHealth Receives 2016 Frost & Sullivan Global Prostate Cancer Diagnostics Technology Innovation Award
GlobeNewswire - Thu Jan 21, 12:06AM CST
MDxHealth SA (Euronext: MDXH.BR) announced today that it received the 2016 Frost & Sullivan Global Technology Innovation Award for its commitment to technological innovation to reduce unnecessary prostate biopsies.
The Analyst's Perspective - November 2015 Issue: The Use of Liquid Biopsy for Diagnosis and Monitoring Gives an Immense Advantage Over Traditional Biopsies - Research and Markets
BusinessWire - Mon Jan 18, 12:27PM CST
Research and Markets (http://www.researchandmarkets.com/research/lkfchr/vital_signs_the) has announced the addition of the "Vital Signs The Analyst's Perspective - November 2015 Issue" report to their offering.
The Analyst's Perspective - November 2015 Issue: The Use of Liquid Biopsy for Diagnosis and Monitoring Gives an Immense Advantage Over Traditional Biopsies
M2 - Mon Jan 18, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/5q9tpq/vital_signs_the) has announced the addition of the "Vital Signs The Analyst's Perspective - November 2015 Issue" report to their offering. This issue of Vital Signs discusses MDxHealth's launch of the SelectMDx Liquid Biopsy Test in Europe, the FDA's approval of a new treatment for non-small cell lung cancer with EGFR mutations, the clamp down on specialty pharmacies by US drug benefit managers, and BGI's strategy redirection for Complete Genomics. MDxHealth launched its new noninvasive test for prostate cancer in Europe via its state-of-the-art lab facility in the Netherlands. The company is offering this testing initially in the Netherlands with plans to offer it to other parts of Europe in early 2016. As a part of this agreement, the company has joined hands with DDL Laboratory, which already offers PCA3 testing in the Netherlands. The Analyst's Perspective by Divyaa Ravishankar, Senior Industry Analyst, Life Sciences Liquid biopsy is the new gold standard for diagnostics. This area has been a hot topic area for several investors, as well as existing and upcoming diagnostic market participants. The use of liquid biopsy for diagnosis and monitoring gives an immense advantage over traditional biopsies, where going to the source is always a concern. By the use of this method, no tissue excision is required. This method picks up biomarkers such as CTCs and ctDNAs, and is found to be as effective as the CT scan techniques where the disease can be detected even before it progresses. The ability to monitor tumor dynamics is far easier using liquid biopsy approaches. Over 2 million prostate biopsies are performed each year, with less than a third testing positive for cancer. Besides the cost, the associated painful and invasive nature of a prostrate biopsy procedure has made several men avoid these tests. A urine-based test, liquid biopsy decreases the complications and the expense of a person undergoing the test. Most importantly, this aids earlier detection. In looking at the efforts invested by MDx Health, the company acquired a Netherlands-based liquid biopsy technology firm called NovioGendix for a value of $X million. One other major disadvantage discovered through end-user research is a high preference toward blood/plasma as the test sample format in comparison to urine, stool, or tissue. This could potentially offset the nature of SelectMDx since the test is based on identifying markers in urine. So far, coverage decisions are unknown for this test. Key Topics Covered: 1. MDxHealth Launches SelectMDx Liquid Biopsy Test in Europe 2. FDA Approves New Treatment for Non-small Cell Lung Cancer with EGFR Mutations 3. US Drug Benefit Managers Clamp Down on Specialty Pharmacies 4. Sequencing Ser vice Provider Stops Planned Instrument Launch, Redirects Strategy Companies Mentioned - DDL Laboratory - MDxHealth For more information visit http://www.researchandmarkets.com/research/5q..._signs_the
World renowned Robotic prostate cancer surgeon in New York supports new study for use of ConfirmMDx
PR Newswire - Tue Jan 12, 2:10AM CST
Dr. David Samadi is a world renowned Robotic prostate cancer surgeon and urologic oncologist in New York. He specializes in the treatment of prostate cancer, as well as other prostate conditions such as benign prostatic hyperplasia. Dr. Samadi supports a new study suggesting that the diagnostic test, ConfirmMDx, is useful for helping to diagnose or rule out prostate cancer.
MDxHealth (R): Grants QIAGEN Rights to MSP Technology for QIAsure Methylation Test for Cervical Cancer Risk
GlobeNewswire - Wed Jun 15, 12:07AM CDT
MDxHealth SA (Euronext: MDXH.BR), announced today that it has granted a non-exclusive worldwide license for its patented methylation-specific PCR (MSP) technology to QIAGEN for use in its new CE-marked QIAsure assay to determine cervical cancer risk.
MDxHealth Secures First Reimbursement Coverage for SelectMDx
GlobeNewswire - Tue Jun 14, 12:13AM CDT
MDxHealth SA (Euronext: MDXH.BR), announced today that it has secured the first U.S. reimbursement coverage agreement for its SelectMDx(TM) for Prostate Cancer test with America's Choice Provider Network, Inc. (ACPN). ACPN is a national provider network with over 1,700 payers, including insurance carriers, third party administrators, health and welfare funds, employer groups and self-insured health plans, providing coverage to 24 million American lives and 750,000 international lives.
MDxHealth (R): Disclosure of the Number of Outstanding Voting Securities
GlobeNewswire - Fri May 20, 12:05AM CDT
MDxHealth SA (NYSE Euronext: MDXH) ("MDxHealth"
announced today, pursuant to Article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated market, that on May 19, 2016, 116,000 new ordinary shares were issued by MDxHealth further to the exercise of 116,000 warrants by employees and consultants of MDxHealth, for an aggregate exercise price of EUR 196,920.00 for all warrants. The exercised warrants were initially issued in April 2011 and May 2012. Taglich Brothers Initiates Coverage on MDxHealth SA
Marketwire Canada - Mon May 09, 8:30AM CDT
NEW YORK, NY--(Marketwired - May 09, 2016) - Taglich Brothers, Inc. announces it initiated coverage of MDxHealth SA (EURONEXT BRUSSELS: MDXH)(OTC: MDXHF).
MDxHealth's ConfirmMDx Stratifies Risk for Aggressive Prostate Cancer
GlobeNewswire - Mon May 09, 12:07AM CDT
MDxHealth SA (Euronext: MDXH.BR) announced today the publication of multicenter validation data demonstrating that ConfirmMDx(R) for Prostate Cancer can aid in the identification of men with clinically significant prostate cancer (PCa) in the journal The Prostate.
MDxHealth Announces Positive Data Supporting Prognostic Value of ConfirmMDx and SelectMDx for Prostate Cancer
GlobeNewswire - Fri May 06, 12:09AM CDT
MDxHealth SA (Euronext: MDXH.BR) is presenting positive data demonstrating the prognostic value of its SelectMDx and ConfirmMDx tests for Prostate Cancer test at the 2016 American Urological Association Annual Meeting hold between 6-10 May 2016 in San Diego, California, USA. These data, which are presented in two separate poster presentations, demonstrate that:
MDxHealth Provides First Quarter 2016 Business Update
GlobeNewswire - Tue May 03, 12:11AM CDT
MDxHealth SA (Euronext: MDXH.BR) today issued its business update for the quarter ended March 31, 2016.
MDxHealth's SelectMDx Study Published in European Urology
GlobeNewswire - Mon Apr 25, 12:08AM CDT
MDxHealth SA (Euronext: MDXH.BR), today announced that data validating the clinical performance of the SelectMDx(TM) for Prostate Cancer test have been published in European Urology.
MDxHealth Partners with Andros Men's Clinic to Offer SelectMDx for Prostate Cancer
GlobeNewswire - Tue Mar 29, 12:08AM CDT
MDxHealth SA (Euronext: MDXH.BR), announced today that it has partnered with Andros Men's Health Clinic (Andros Mannenkliniek) in The Netherlands to offer the SelectMDx for Prostate Cancer test to their patients.
MDxHealth Launches SelectMDx "Liquid Biopsy" Test in the United States
GlobeNewswire - Thu Mar 17, 1:05AM CDT
MDxHealth SA (Euronext: MDXH.BR), today announced the commercial launch of its SelectMDx(TM) for Prostate Cancer test in the United States as a laboratory developed test (LDT). Testing will be conducted at MDxHealth's state-of-the-art CAP and CLIA accredited laboratory facilities in Irvine, California.
MDxHealth Presents SelectMDx(TM) Results from Multicenter Validation Study at the 2016 Annual EAU Congress
GlobeNewswire - Mon Mar 14, 1:11AM CDT
MDxHealth SA (Euronext: MDXH.BR), announced today that positive results of a prospective, multicenter validation study of SelectMDx(TM) for Prostate Cancer were presented at the 2016 Annual European Association of Urology (EAU) Congress, March 11-15 in Munich, Germany.
MDxHealth Appoints Global Commercial Team for SelectMDx
GlobeNewswire - Wed Mar 09, 12:04AM CST
MDxHealth SA (Euronext: MDXH.BR) announced today that it has appointed a global commercial team to drive the launch of the Company's new non-invasive, urine-based test, SelectMDx(TM) for Prostate Cancer.
MDxHealth Announces Conference Participation for First Half 2016
GlobeNewswire - Thu Jan 28, 2:06AM CST
MDxHealth SA (Euronext: MDXH.BR), announced today that it will be participating at the following key conferences during the first half of 2016:
Frost & Sullivan Applauds MDxHealth's Commitment to Improving Prostrate Cancer Detection through its ConfirmMDx and SelectMDx Tests
PR Newswire Europe - Thu Jan 21, 8:01AM CST
A positive ConfirmMDx or SelectMDx test can indicate whether the patient is at risk of harboring an aggressive or non-aggressive cancer
MDxHealth Receives 2016 Frost & Sullivan Global Prostate Cancer Diagnostics Technology Innovation Award
GlobeNewswire - Thu Jan 21, 12:06AM CST
MDxHealth SA (Euronext: MDXH.BR) announced today that it received the 2016 Frost & Sullivan Global Technology Innovation Award for its commitment to technological innovation to reduce unnecessary prostate biopsies.
The Analyst's Perspective - November 2015 Issue: The Use of Liquid Biopsy for Diagnosis and Monitoring Gives an Immense Advantage Over Traditional Biopsies - Research and Markets
BusinessWire - Mon Jan 18, 12:27PM CST
Research and Markets (http://www.researchandmarkets.com/research/lkfchr/vital_signs_the) has announced the addition of the "Vital Signs The Analyst's Perspective - November 2015 Issue" report to their offering.
The Analyst's Perspective - November 2015 Issue: The Use of Liquid Biopsy for Diagnosis and Monitoring Gives an Immense Advantage Over Traditional Biopsies
M2 - Mon Jan 18, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/5q9tpq/vital_signs_the) has announced the addition of the "Vital Signs The Analyst's Perspective - November 2015 Issue" report to their offering. This issue of Vital Signs discusses MDxHealth's launch of the SelectMDx Liquid Biopsy Test in Europe, the FDA's approval of a new treatment for non-small cell lung cancer with EGFR mutations, the clamp down on specialty pharmacies by US drug benefit managers, and BGI's strategy redirection for Complete Genomics. MDxHealth launched its new noninvasive test for prostate cancer in Europe via its state-of-the-art lab facility in the Netherlands. The company is offering this testing initially in the Netherlands with plans to offer it to other parts of Europe in early 2016. As a part of this agreement, the company has joined hands with DDL Laboratory, which already offers PCA3 testing in the Netherlands. The Analyst's Perspective by Divyaa Ravishankar, Senior Industry Analyst, Life Sciences Liquid biopsy is the new gold standard for diagnostics. This area has been a hot topic area for several investors, as well as existing and upcoming diagnostic market participants. The use of liquid biopsy for diagnosis and monitoring gives an immense advantage over traditional biopsies, where going to the source is always a concern. By the use of this method, no tissue excision is required. This method picks up biomarkers such as CTCs and ctDNAs, and is found to be as effective as the CT scan techniques where the disease can be detected even before it progresses. The ability to monitor tumor dynamics is far easier using liquid biopsy approaches. Over 2 million prostate biopsies are performed each year, with less than a third testing positive for cancer. Besides the cost, the associated painful and invasive nature of a prostrate biopsy procedure has made several men avoid these tests. A urine-based test, liquid biopsy decreases the complications and the expense of a person undergoing the test. Most importantly, this aids earlier detection. In looking at the efforts invested by MDx Health, the company acquired a Netherlands-based liquid biopsy technology firm called NovioGendix for a value of $X million. One other major disadvantage discovered through end-user research is a high preference toward blood/plasma as the test sample format in comparison to urine, stool, or tissue. This could potentially offset the nature of SelectMDx since the test is based on identifying markers in urine. So far, coverage decisions are unknown for this test. Key Topics Covered: 1. MDxHealth Launches SelectMDx Liquid Biopsy Test in Europe 2. FDA Approves New Treatment for Non-small Cell Lung Cancer with EGFR Mutations 3. US Drug Benefit Managers Clamp Down on Specialty Pharmacies 4. Sequencing Ser vice Provider Stops Planned Instrument Launch, Redirects Strategy Companies Mentioned - DDL Laboratory - MDxHealth For more information visit http://www.researchandmarkets.com/research/5q..._signs_the
World renowned Robotic prostate cancer surgeon in New York supports new study for use of ConfirmMDx
PR Newswire - Tue Jan 12, 2:10AM CST
Dr. David Samadi is a world renowned Robotic prostate cancer surgeon and urologic oncologist in New York. He specializes in the treatment of prostate cancer, as well as other prostate conditions such as benign prostatic hyperplasia. Dr. Samadi supports a new study suggesting that the diagnostic test, ConfirmMDx, is useful for helping to diagnose or rule out prostate cancer.
